- Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Aticaprant 10 mg as Adjunctive Therapy in Adult Participants with Major Depressive Disorder (MDD) with Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy and an Open-label Long-term Extension Treatment with Aticaprant
This study is looking into a new medication, Aticaprant, for adults with depression who feel little pleasure and whose current treatments aren't working well enough. It aims to see if Aticaprant, taken with their usual antidepressant, can improve their mood and help them feel better.
For: Major Depressive Disorder (MDD) with Moderate-to-severe AnhedoniaBelgium · Bulgaria · Poland - Ongoing, recruitingHuman Pharmacology (Phase I)- Other
An Open-Label, Single-Center, Single-Dose Study to Assess the Absolute Oral Bioavailability and Pharmacokinetics of Aticaprant Administered as an Oral Tablet and an Intravenous Infusion Microdose of 14C-Aticaprant in Healthy Participants
This study is looking at how a new drug, Aticaprant, is absorbed by the body. Researchers want to compare how well it enters the bloodstream when taken as a tablet versus a very small amount given directly into a vein. This helps them understand the best way to give the medicine.
For: Healthy Adult ParticipantsBelgium - Ongoing, recruitingTherapeutic confirmatory (Phase III)
An Open-label, Long-term, Safety and Efficacy Study of Aticaprant as Adjunctive Therapy in Adult and Elderly Participants With Major Depressive Disorder (MDD)
This study is testing a new medicine, JNJ-67953964, for adults with depression. It aims to see if it's safe and effective when added to their usual treatment over a long period. We'll monitor health, mood, and any side effects.
For: Major Depressive DisorderSweden · Hungary · France - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Randomized, Double-blind, Multicenter, Placebo-controlled Study of Adjunctive Aticaprant Plus an Antidepressant for Relapse Prevention in Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia
This study is looking into a new medication, JNJ-67953964, to help stop depression from coming back in people who also feel unable to experience pleasure. It compares this new drug with a dummy pill, alongside standard antidepressant treatment, to see how well it works.
For: Major Depressive Disorder (MDD) with Moderate-to-severe AnhedoniaBulgaria · Greece · Spain